INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Innoviva, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$21.08+0.30 (+1.44%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
Innoviva, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Revenue | $226.29M | $233.84M | $236.48M | $244.10M | $241.26M | $241.13M | $241.73M | $245.38M | $241.88M | $240.40M | $238.85M | $223.90M | 51.4% | -6.2% |
| Net product sales | $199.50M | $183.22M | $172.13M | $142.00M | $122.53M | $108.69M | $97.49M | $88.23M | $74.11M | $68.19M | $60.62M | $55.53M | 45.3% | +62.8% |
| XACDURO | $96.34M | $84.68M | $74.39M | $49.04M | $35.01M | $26.62M | $21.07M | $15.77M | $6.58M | – | $2.00M | – | 21.9% | +175.2% |
| GIAPREZA | $80.54M | $75.57M | $73.61M | $70.13M | $65.45M | $61.23M | $55.04M | $52.06M | $46.28M | $44.38M | $41.29M | $42.40M | 18.3% | +23.1% |
| XERAVA [Member] | $21.57M | $21.92M | $23.52M | $22.38M | $21.74M | $20.84M | $21.39M | $20.45M | $21.29M | $19.59M | $17.32M | $16.28M | 4.9% | -0.8% |
| License and other revenue | $14.21M | $3.63M | $2.72M | $2.42M | $6.44M | $20.03M | $19.49M | – | – | – | – | – | 3.2% | +120.7% |
| ZEVTERA [Member] | $1.06M | $1.05M | $610.00K | $452.00K | $339.00K | $0 | $0 | – | – | – | – | – | 0.2% | +212.7% |
| License revenue | – | – | – | – | – | – | – | $19.14M | $14.51M | $3.00M | $11.00M | $11.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Innoviva's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.